Company Description

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics.

It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.

The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022.

Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Revelation Biosciences, Inc.

Country	United States
Founded	2020
Industry	Biotechnology
Sector	Healthcare
Employees	9
CEO	James Rolke

Contact Details

Address: 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 United States
Phone	650 800 3717
Website	revbiosciences.com

Stock Details

Ticker Symbol	REVB
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1810560
CUSIP Number	76135L804
ISIN Number	US76135L8046
Employer ID	84-3898466
SIC Code	2834

Key Executives

Name	Position
James M. Rolke	Chairman and Chief Executive Officer
Chester Stanley Zygmont III	Chief Financial Officer and Corporate Secretary
Sandra Vedrick	Vice President of Human Resources and Investor Relations
Carol Odle	Senior Director of Clinical Projects

Latest SEC Filings

Date	Type	Title
Feb 6, 2026	PRE 14A	Other preliminary proxy statements
Jan 30, 2026	S-3	Registration statement under Securities Act of 1933
Jan 29, 2026	8-K	Current Report
Jan 22, 2026	8-K	Current Report
Jan 20, 2026	SCHEDULE 13G	Filing
Dec 3, 2025	8-K	Current Report
Nov 14, 2025	SCHEDULE 13G	Filing
Nov 12, 2025	S-8	Securities to be offered to employees in employee benefit plans
Nov 10, 2025	DEF 14A	Other definitive proxy statements
Nov 6, 2025	8-K	Current Report

View All SEC Filings